Shots:

• The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib- 600mg- bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with an epithelial ovarian- fallopian tube or primary peritoneal cancer
• The P-III ARIEL3 study results: IIT population & BRCA mutation- Mean QA-PFS in (12.02 vs 5.74 & 15.28 vs 5.92 mos.); Mean Q-TWiST (13.32 vs 6.44 & 16.42 vs 6.70 mos.); Q-TWiST (13.16 vs 6.40 & 16.24 vs 6.68 mos.) respectively
• Rubraca (rucaparib) is an oral PARP1- PARP2 and PARP3 inhibitor and has received FDA’s approval as a monothx. for the maintenance treatment of recurrent epithelial ovarian- fallopian tube- or primary peritoneal cancer in Apr’18

Ref: BusinessWire | Image: Linkedin